{
    "clinical_study": {
        "@rank": "75549", 
        "acronym": "META2", 
        "arm_group": {
            "arm_group_label": "Cisplatin - Metronomic Cyclophosphamide", 
            "arm_group_type": "Experimental", 
            "description": "Cisplatin 25 mg/m\u00b2 from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks"
        }, 
        "brief_summary": {
            "textblock": "Study assessing efficacy of a Cisplatine- M\u00e9tronomic cyclophosphamide treatment in Patients\n      with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and\n      Taxanes."
        }, 
        "brief_title": "Phase II Pilot Study Assessing Efficacy of a Cisplatin - M\u00e9tronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes", 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Performance status < 2,\n\n          -  Patient with metastatic breast cancer stade IV triple negative histologically\n             confirmed\n\n          -  Measurable or not disease but radiologically evaluable (RECIST 1.1),\n\n          -  Negative Hormonal Receptors (Estrogens and/or Progesterone),\n\n          -  HER-2 negative (Score 0 or 1 by Immunochemistry (IHC), negative FISH if score IHC 2),\n\n          -  Patient exposed to anthracyclines and/or taxanes in neo-adjuvant or adjuvant setting,\n\n          -  Patient with a progression and for whom anthracyclines and/or taxanes treatment\n             cannot be delivered and according to a resistance defined as :\n\n          -  In the last 12 months after the last dose of taxanes or anthracyclines in adjuvant or\n             neoadjuvant setting or,\n\n          -  During or after a first metastatic chemtotherapy line and where taxanes and\n             anthracyclines cannot be delivered according to :\n\n          -  either a secondary resistance after an initial response to chemotherapy but a relapse\n             observed either during the treatment or in the 4 months after the end of\n             chemotherapy.\n\n          -  either a sensitivity to treatment defined by a relapse after more than 4 months after\n             the first chemotherapy metastatic line,\n\n          -  either intolerance to anthracyclines (doxorubicin 240-400 mg/m\u00b2 ou equivalent to\n             doxorubicin (epirubicin) 300-550mg/m\u00b2)\n\n          -  Patient non previously treated by platinum salts,\n\n          -  Hematological Functions: Neutrophiles \u2265 1,5.109/L, Platelets \u2265 100.109/L, Leucocytes\n             > 3 000/mm3, Hb > 9g/dL, Hepatic Functions : total Bilirubin \u2264 1,5 time upper normal\n             value (UNV), ASAT \u2264 2 ,5 time UNV, ALAT \u2264 2,5 time UNV, Alkaline Phosphatase \u2264 2,5\n             time UNV (< 5 time UNV if case of hepatic metastasis), Renal Functions: Serum\n             Creatinine \u2264 1,5 time UNV (and if value > 1,5 time UNV, so Clearance \u2265 60 mL/min) or\n             Clearance \u2265 40 mL/min in case of RMI,\n\n          -  Patient signed the consent study form,\n\n          -  Patient affiliated to a social security regimen (law of 9 August 2004).\n\n        Exclusion Criteria:\n\n          -  Male Patients,\n\n          -  Unknown hormonal Receptors\n\n          -  Positive HER-2 (Score 3 in IHC or positive FISH)\n\n          -  Pregnant or breastfeeding patient, or in age of pregnancy or predicting to be\n             pregnant in the 6 months after the end of treatment,\n\n          -  Patient not using contraceptive treatment during the treatment or after the 6 months\n             after the end of treatment,\n\n          -  Patient is a ward,\n\n          -  Patient suffering from a non compatible disease with the enrollment in the study,\n\n          -  Cardiac, renal, medullar, respiratory or hepatic insufficiency, clinically\n             significant cardiovascular disease (including myocardiac infarct, unstable angina,\n             symptomatic congestive heart failure, uncontrolled cardiac arrhythmia) < 1 year\n             before the study enrollment or randomisation,\n\n          -  Patient with pulmonary lymphangitis or symptomatic pleural effusion (grade\u22652),\n             meningeal known carcinoma or symptoms of cerebromeningeal invasion, brain metastases\n             unless treatment and stability for at least 4 weeks (no steroids or anti-convulsive).\n\n          -  Uncontrolled diabetes,\n\n          -  Psychiatric or neurological significant abnormality,\n\n          -  Peripheric Neuropathy > grade 2,\n\n          -  Antecedent of hypersensibility to one of study treatment or one of used excipients,\n\n          -  Urinary tract infection or acute hemorrhagic cystitis in progress\n\n          -  Concomitant treatment with a medicine containing phenytoin or medication received in\n             the context of a trial, or participation in another therapeutic clinical trial within\n             <30 days prior treatment with chemotherapy.\n\n          -  Geographically unstable patient in the next 6 months or remaining distance to the\n             treatment center making it difficult to follow in the study,\n\n          -  Known history of abuse of narcotic or other drug or alcohol\n\n          -  History of surgery within 28 days before the start of treatment,\n\n          -  Patient unwilling or unable to comply with the requirements of the study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910844", 
            "org_study_id": "CJP 4.2 - META2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cisplatin - Metronomic Cyclophosphamide", 
                "description": "25 mg/m\u00b2 I.V. from day 1 to day 3 - total dose = 75 mg/m\u00b2 every 3 weeks", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cisplatin - Metronomic Cyclophosphamide", 
                "description": "Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 -  total dose 2100 mg every 3 weeks", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Endoxan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Cyclophosphamide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "triple negative breast cancer", 
            "late-relapse"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jmnabholtz@cjp.fr", 
                    "last_name": "Jean-Marc NABHOLTZ, MD, MSc", 
                    "phone": "+33473278482"
                }, 
                "contact_backup": {
                    "email": "nassera.chalabi@cjp.fr", 
                    "last_name": "Nassera CHALABI, PhD", 
                    "phone": "+33473278454"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurillac", 
                        "country": "France", 
                        "zip": "15000"
                    }, 
                    "name": "Centre Hospitalier Henri Mondor"
                }, 
                "investigator": [
                    {
                        "last_name": "Jean-Marc NABHOLTZ, MD, MSc", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Daniela BURLACU, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "drmichelkareh@yahoo.fr", 
                    "last_name": "Michel KAREH, MD", 
                    "phone": "+33471043336"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurillac", 
                        "country": "France", 
                        "zip": "15000"
                    }, 
                    "name": "Centre M\u00e9dico-Chirurgical Les Tronqui\u00e8res"
                }, 
                "investigator": {
                    "last_name": "Michel KAREH, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jmnabholtz@cjp.fr", 
                    "last_name": "Jean-Marc NABHOLTZ, MD, MSc", 
                    "phone": "4-73-27-84-82", 
                    "phone_ext": "+33"
                }, 
                "contact_backup": {
                    "email": "nassera.chalabi@cjp.fr", 
                    "last_name": "Nass\u00e9ra CHALABI, PhD", 
                    "phone": "4-73-27-84-54", 
                    "phone_ext": "+33"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }, 
                    "name": "Centre Jean Perrin"
                }, 
                "investigator": [
                    {
                        "last_name": "Jean-Marc NABHOLTZ, MD, MSc", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mohun R.K. BAHADOOR, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Philippe CHOLLET, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Marie-Ange MOURET-REYNIER, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pascale DUBRAY-LONGERAS, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Isabelle VAN PRAAGH-DOREAU, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Daniela BURLACU, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jmnabholtz@cjp.fr", 
                    "last_name": "Jean-Marc NABHOLTZ, MD, MSc", 
                    "phone": "+33473278482"
                }, 
                "contact_backup": {
                    "email": "nassera.chalabi@cjp.fr", 
                    "last_name": "Nassera CHALABI, PhD", 
                    "phone": "+33473278454"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Puy-en-Velay", 
                        "country": "France", 
                        "zip": "43000"
                    }, 
                    "name": "Centre Hospitalir Emile Roux"
                }, 
                "investigator": [
                    {
                        "last_name": "Jean-Marc NABHOLTZ, Md, MSc", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Brigitte MONANGE, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jmnabholtz@cjp.fr", 
                    "last_name": "Jean-Marc NABHOLTZ, MD, MSc", 
                    "phone": "+33473278482"
                }, 
                "contact_backup": {
                    "email": "nassera.chalabi@cjp.fr", 
                    "last_name": "Nassera CHALABI, PhD", 
                    "phone": "+33473278454"
                }, 
                "facility": {
                    "address": {
                        "city": "Montlu\u00e7on", 
                        "country": "France", 
                        "zip": "03100"
                    }, 
                    "name": "Centre Hospitalier de Montlu\u00e7on"
                }, 
                "investigator": [
                    {
                        "last_name": "Jean-Marc NABHOLTZ, MD, MSc", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Pascale DUBRAY-LONGERAS, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "jmnabholtz@cjp.fr", 
            "last_name": "Jean-Marc NABHOLTZ, MD, MSc", 
            "phone": "4-73-27-84-82", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "nassera.chalabi@cjp.fr", 
            "last_name": "Nass\u00e9ra CHALABI, PhD", 
            "phone": "7-73-27-84-54", 
            "phone_ext": "+33"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Committee for the Protection of Personnes", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response rate of cisplatine - metronomic cyclophosphamide treatment", 
            "safety_issue": "No", 
            "time_frame": "12 months and 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910844"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease free progression", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Number of Participants with Adverse Events", 
                "measure": "Safety profile of cisplatin - metronomic cyclophosphamide association", 
                "safety_issue": "Yes", 
                "time_frame": "12 months and 6 weeks"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Predictive factors to response and/or resistance treatment", 
                "safety_issue": "No", 
                "time_frame": "12 months and 6 weeks"
            }
        ], 
        "source": "Centre Jean Perrin", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Jean Perrin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}